homocysteine and cysteine-homocysteine-are a risk factor for CHD, stroke, and possibly other forms of arterial and venous vascular disease. 2 Low blood levels of folate appear to be a particularly strong environmental determinant of tHCY levels in many populations. 2 Genetic factors also contribute to tHCY levels, and recent studies have focused on a common inherited Variation in the enzyme MTHFR. MTHFR catalyzes the reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a reaction that contributes Substrates for the remethylation of homocysteine to methionine by methionine synthase. Kang et al 3 -5 reported that up to 5% of the population has an inherited thermolabile form of MTHFR, one that is associated with reduced enzyme activity and premature CHD. Thermolabile MTHFR reportedly accounts for =»25% to 30% of elevated tHCY in patients with premature vascular disease. 6 A common single-base-pair change, cytosine (C) to thymine (T), at nucleotide 677 of the MTHFR gene was recently identified, 7 and persons homozygous for the T allele were more likely to have thermolabile MTHFR and elevated tHCY than persons with other genotypes. Thus, the C 677 ->r polymorphism in the MTHFR gene may be a genetic risk factor for premature cardiovascular disease. 7 
· 8
Selected Abbreviations and Acronyms CHD = coronary heart disease CI = confldence interval MI = myocardial infarction MTHFR = 5,10-methylenetetrahydrofolate reductase OR = odds ratio tHCY = total homocysteine Although the strong inverse correlation between folate and tHCY Supports the hypothesis that reduced folate Status may be a risk factor for CHD, those few studies that examined this relationship have yielded conflicting results. 9 - 14 Similarly, while some investigations have found the risk of vascular disease to be increased among persons homozygous for the MTHFR T 677 allele, 15 -17 others have not.
18
- 20 We studied the relationship of plasma tHCY, plasma folate, and the MTHFR C 6?7 ->T polymorphism to the risk of acute MI among young women in a population-based case-control study.
Methode Subjects
The data for this report were drawn from a study of incident cardiovascular disease (MI and stroke) among women 18 to 44 years old residing in King, Pierce, and Snohomish counties, Washington state. Eligible MI case patients were women diagnosed with a first fatal or nonfatal MI between July l, 1991, and February 28,1995, who had no prior history of major CHD or stroke. We identified potential case patients through monthly review and abstraction of discharge diagnoses of acute ischemic heart disease provided by all hospitals within the study region, incident reports from emergency medical Service Systems, and death certificates listing out-of-hospital deaths from cardiovascular disease and related conditions. We identified 208 eligible MI patients with definite or probable MI on the basis of the criteria used by the Cardiovascular Health Study, 21 of whom 161 were living at the time that we initiated recruitment. We recruited 107 of these women into the study, 4 were not approached at the request of their physicians, and the remainder either refused to participate (n=40) or could not be located (n=10).
We used random-digit telephone dialing to identify a sample of women 18 to 44 years old who were residents of King, Pierce, or Snohomish counties during the case diagnosis period. Briefly, telephone numbers were generated at random with a Computer algorithm, and a household census to ascertain women meeting the eligibility criteria was completed for 94.9% of the residences contacted. Among the eligible women identified, we attempted to enroll 691 at random, frequency matched to the combined age distribution of all cardiovascular disease patients recruited for the study. Only l woman from each household was selected for recruitment. Seven of the 691 women were excluded because of a prior history of major cardiovascular disease (n=6) or inability to communicate in English (n=l). Of the remaining 684 women, 526 were recruited into the study, for an estimated overall response rate of 72.8% (94.9% of 526/684).
Data Collection
Participating case patients and control subjects were interviewed in person regarding histories of known or suspected cardiovascular risk factors, including histories of physiciandiagnosed diabetes, hypertension, or high cholesterol; cigarette Smoking; height and weight; menstrual history; contraceptive practices; alcohol consumption; physical activity; history of MI in first-degree relatives; and demographic characteristics. No Information was collected on dietary or nutritional Supplement sources of vitamins. The structured interview elicited Information only from the time period before the MI in each case patient. Hence, in this report we use the term "current" to describe characteristics of each patient äs of the date that she had her MI (or equivalent date for control subjects). In addition to the in-person interview, we also obtained a 30-mL venous blood specimen from 79 MI case patients and 391 control subjects into EDTA-treated vacuum tubes; aliquots of plasma and buffy coat were frozen at -70°C. Case blood samples were obtained at least 3 months after the event (mean, 8 months; median, 6.5 months).
Laboratory Analyses
Plasma tHCY concentrations were determined by highpressure liquid chromatography and electrochemical detection äs previously described. 22 Plasma folate and vitamin B 12 concentrations were measured with the Quantaphase II Assay System (Bio-Rad Laboratories). Genomic DNA was extracted from buffy-coat aliquots by established methods. 23 The C 677 -^T Variation in the MTHFR gene was determined äs described by Frosst et al. 7 tHCY measurements were available for 79 case patients and 386 control subjects, folate and vitamin B 12 measurements were available for 77 case patients and 382 control subjects, and MTHFR genotyping for 79 case patients and 379 control subjects. We also measured HDL cholesterol, LDL cholesterol, and triglycerides, by Standard methods, on a subset of case patients (n=63) and control subjects (n=140) selected at random. 24 All laboratory analyses were conducted blind äs to whether a sample came from a case patient or control subject.
Statistical Analysis
For initial analyses of the relationship between MI risk and concentrations of tHCY, folate, and vitamin B 12 , we compared case patients and control subjects with respect to the mean concentrations of these compounds. The distributions of folate and vitamin B 12 were skewed, but because case-control comparisons of geometric means and arithmetic means yielded identical results, only the latter are presented. For the risk of MI associated with tHCY, folate, and vitamin B 12 , we classified the data into approximate quartiles based on the distribution of these compounds among case patients. We then used unconditional logistic regression models to estimate ORs and 95% CIs for each quartile. 25 For each of these compounds, we investigated potential confounding by age (in years); education (less than College, College, postcollege); ethnicity (non-Hispanic white, black, other); cigarette smoking (current, past, never); obesity (body mass index >27.3 kg/m 2 versus <27.3 kg/m 2 ); currently receiving medical treatment for hypertension, diabetes, or high cholesterol; menopausal Status (postmenopausal versus premenopausal); average frequency of alcohol use in the previous year (three or more times per week, less than three per week, none); average frequency of vigorous exercise in the previous year (once per week, less than once per week, never); and current use of oral contraceptives (yes, no). Potential confounding by plasma lipid measures was investigated within the subset of case patients and control subjects with data available on those characteristics. Except for age, terms for confounders were retained in the model if they produced an important change in the coefficient for a particular plasma measurement. To evaluate the extent to which the pattern of ORs for tHCY, folate, or vitamin B 12 were consistent with a linear trend in risk, we computed the difference in the loglikelihoods between hierarchical models containing three indicator terms and models containing a single term with four levels (0, l, 2, 3) corresponding to each quartile. In this approach, the smaller the diiference in log-likelihoods, the strenger the evidence that the patterns of ORs are consistent with a linear trend. We also examined the extent to which associations with tHCY, folate, and vitamin B t2 varied by 21 8 Values are percent Percents may not add up to 100 because of roundmg *Average over year before diagnosis or reference date whether a woman was a current cigarette smoker, obese, or had a first-degree relative with a history of MI, these charactenstics were the only established cardiovascular nsk factors for which we had sufficient numbers of case patients and control subjects to mvesügate heterogeneity m nsk Likelihood ratio tests were used to estimate the extent to which chance might account for any differences we observed in associations between analytes and MI nsk according to smokmg, obesity, or famdy history Status We exammed the distnbution of MTHFR genotypes among control subjects and the relationship of genotype to tHCY, folate, and vitamm B 12 concentrations ORs for the association of homozygous T 677 and heterozygous T 677 genotypes, compared with homozygous C genotypes, were estimated by the Mantel-Haenszel method All analyses of MTHFR genotypes were restncted to non-Hispanic whites to reduce the influence of genetic heterogeneity on our results
Results
The study populaüon was largely white, not of Hispanic ongm, but blacks were overrepresented among the case patients (Table 1) . Case patients were much more hkely than control subjects to be currently receivmg medications for hypertension, diabetes, or high cholesterol; to be postmenopausal; and to have a first-degree relative with a history of MI. Cigarette smokmg, obesity, and family history of MI were extremely comnion among case patients. »»70%, 60%, and 54% of the patients reported these charactenstics, respectively, compared with «21%, 27%, and 30% of control subjects. Case patients also tended to have less formal education and were less hkely to be current users of oral contraceptives and to participate m regulär vigorous physical activity than control subjects Compared with control subjects, case patients had higher mean tHCY concentrations (13.4±5. Among control subjects, tHCY concentrations were mversely associated with concentrations of folate after adjustment for vitamm B 12 (/-=-.397, F=.0001), whereas vitamm B 12 concentrations were not related to tHCY after adjustment for folate (r=-.082, P=.ll).
The nsk of MI adjusted for age, diabetes, cigarette smokmg, and obesity among young women mcreased with increasing quartile of tHCY and decreased with mcreasmg quartile of folate (Table 2 ), the patterns of The results also did not diifer after exclusion of the few women who were being treated for hypertension or were taking oral contraceptive puls. We also conducted analyses in which we (1) excluded the 20% of case patients for whom the blood draw was performed relatively close to the event (3 to 4 months) or relatively distant from the event (>14 months) and (2) estimated associations separately for case patients with blood drawn within 6.5 months of the event and for case patients with blood drawn after this interval; these analyses resulted in trivial changes in the associations. The ORs for eleväted tHCY (s!2.6 μπιοΙ/L) among smokers (55 case patients and 83 control subjects) and nonsmokers (24 case patients and 303 control subjects) were similar: 1.92 (95% CI, 0.91 to 4.96) and 1.86 (95% CI, 0.66 to 5.22) (heterogeneity, x 2 Uf =0.059, P=.808), äs were the ORs among women with (43 case patients and 112 control subjects) and without (34 case patients and 266 control subjects) a family history of MI: 2.07 (95% CI, 0.89 to 4.82) and 2.07 (95% CI, 0.91 to 4.73) (heterogeneity, Χ 2 ω/ = 0·000, Ρ=.999). Among obese women (46 case patients and 104 control subjects), there was no association with tHCY >12.6 μηιοΙ/L (OR, 1.14; 95% CI, 0.48 to 2.71), whereas among nonobese women (33 case patients and 279 control subjects), the OR was eleväted (OR, 3.20; 95% CI, 1.35 to 7.57) (heterogeneity, χ%·=4.451, f>=.035). The ORs for eleväted folate (a8.39 nmol/L) did not vary according to whether or not the woman smoked, was obese, or had a family history of MI.
About one eighth (12.7%) of the 338 non-Hispanic white control subjects were homozygous and 41.7% were heterozygous for the MTHFR T 677 allele (Table 3) . Folate concentrations were 30% lower and tHCY concentrations were 25% higher among women homozygous for MTHFR T 677 compared with women possessing at least one copy of the C 677 allele. The excess tHCY concentration among MTHFR T 677 homozygotes was present only among women with low plasma folate (<8.39 nmol/L). Among all non-Hispanic white control subjects, 30% of women with tHCY >15.6 μιηοΙ/L (the 90th percentile among control subjects), compared with 10% of women with tHCY below this level, were honiO2ygous for MTHFR T 677 . Among the non-Hispanic white MI case patients, MTHFR T 677 homozygotes had tHCY levels that were similar to other case patients (mean±SD, 13.2±6.9 versus 13.4±4.9 μηιοΙ/L, respectively) but had lower folate levels (mean±SD, 10.3±5.9 versus 13.0±14.8 μιηοΙ/L, respectively). 
The distribution of MTHFR C
677 -*T genotype was similar among non-Hispanic white case patients and control subjects, and the risk of MI was not associated with homozygosity or heterozygosity for the T 677 allele (Table 4 ). This result was unchanged when we excluded the women who reported currently receiving medication for hypertension, diabetes, or high cholesterol. No association was observed after the population was stratified according to plasma folate level (data not shown).
Discussion
We observed an increasing risk of MI among young women with increasing plasma tHCY concentration, and in particular an approximately twofold increased risk for women with plasma tHCY concentrations of >15.6 μιηοΙ/L (the 90th percentile of the distribution among control subjects in our study). This association is consistent with the accumulated evidence supporting tHCY äs a risk factor for CHD but is somewhat weaker than has been observed in the few, relatively small previous studies that presented results for women 11,12,26,27 important features of these earlier studies that differ from the present report are the inclusion of (1) older women (predominantly or entirely postmenopausal), 12 · 26 (2) case patients (but not control subjects) required to have a strong family history of CHD, 27 and (3) 27 That traditional risk factors such äs cigarette Smoking and obesity appear to account for the great majority of MI case patients in very young women could also contribute to our finding a weaker association between MI and tHCY than might be predicted from previous studies. Regarding the possible modifying role of these important estab- Our findings for tHCY, folate, or vitamin B n may not reflect the relationships with MI that would be observed had we used a prospective study design, but such an approach is not feasible given the extremely infrequent occurrence of MI in young women. We did not attempt to measure whether or how the diets of MI patients had changed after their events. If diets of patients improved and included higher intake of folate, our results would represent underestimates of the true associations. Alternatively, if the diets of patients included less folate than before the MI, our results might overestimate the true associations. Given the generally good agreement between results of previous prospective and retrospective studies of tHCY and CHD, it seems unlikely that the associations we observed are very different from those that we would have found had measurements been obtained before the ML Our participation rates were relatively low, but our results would be biased only to the extent that case patients and control subjects would differ with respect to the association between participation and plasma tHCY, folate, and vitamin Bi 2 concentrations. Among the women we interviewed, we did not identify any differences in demographic characteristics or cardiovascular risk factors between the women who did and did not provide a blood sample (data not shown). Finally, elevated tHCY could be part of the causal path through which smoking, diabetes, and obesity exert their respective causal effects on MI, and thus we may have underestimated the association with tHCY when we included these characteristics in our logistic models. However, there are other, more firmly established mechanisms through which smoking, diabetes, and obesity affect MI risk. In addition, inclusion of tHCY in the logistic regression models caused minimal change in the coefficients for these factors (data not shown), making it unlikely that elevated tHCY mediales more than a very small proportion of the effect of smoking, diabetes, and obesity on MI risk in our population. Hence, adjustment for smoking, diabetes, and obesity was necessary to avoid overestimating the independent association between tHCY and MI in young women.
Consistent The seven reports to date have examined different manifestations of vascular disease and different sexes and ages of patients, and varied considerably in size, yet these design features do not clearly distinguish studies that have observed an association from those that have not. Positive and negative studies also do not appear to differ consistently in the contribution of MTHFR T 677 to elevated tHCY: 40% and 16% of subjects with elevated tHCY carried two copies of the MTHFR T 677 allele in the Danish 15 and Irish 17 studies, respectively, compared with 21% and 30% in the Physicians Health Study 20 and our study, respectively. If the association between the MTHFR polymorphism and elevated tHCY depends on the amount of 5,10-methylenetetrahydrofolate available to the enzyme, it may be that an association between the homozygous T 677 genotype will be observed only among persons with low folate intake. Two studies that reported no overall association with homozygosity for MTHFR T 677 also did not find compelling evidence of an association among persons with low folate intake, 19 · 20 but the sample sizes were limited. Populations also may differ in the extent to which homozygosity for MTHFR T 677 is associated with the thermolabile MTHFR phenotype. In that regard, it is interesting to note that those studies that observed an association were conducted in populations that potentially are rnore genetically homogeneous 15 ' 17 than those studies (including ours) that failed to find an association. 18 - 20 Finally, given that clinical trials have not been conducted to determine whether lowering tHCY levels can reduce cardiovascular disease occurrence, the causal role of this risk factor has not been fully established. If tHCY in fact is not causally related to cardiovascular disease, then no association would be expected between MI risk and the C 677 -^T polymorphism in the MTHFR gene.
The growmg evidence supporting a role for low folate m the occurrence of cardiovascular disease is likely to lead to randomized tnals to provide definitive tests of this hypothesis 31 Whether mdividuals who carry two copies of the MTHFR T 677 allele are particularly susceptible to the putative adverse cardiovascular effects of low folate is still unclear Thus, randomized tnals should be complemented by additional expenmental and observational studies designed to clanfy the role of this genetic charactenstic and other potential mhented mfluences on folate metabohsm m the association between folate, tHCY, and cardiovascular disease nsk
